August 16, 2021

Reza Zadno, Ph.D. Chief Executive Officer PROCEPT BioRobotics Corporation 900 Island Drive Redwood City, CA 94065

Re: PROCEPT BioRobotics

Corporation

Amendment No. 1 to Draft Registration

Statement on Form S-1

Submitted July 29,

2021

CIK No. 0001588978

Dear Dr. Zadno:

We have reviewed your amended draft registration statement and have the following

comments. In some of our comments, we may ask you to provide us with information so we

may better understand your disclosure.

Please respond to this letter by providing the requested information and either submitting

an amended draft registration statement or publicly filing your registration statement on

EDGAR. If you do not believe our comments apply to your facts and circumstances or do not

believe an amendment is appropriate, please tell us why in your response.

After reviewing the information you provide in response to these comments and your

amended draft registration statement or filed registration statement, we may have additional

comments.

Amendment No. 1 to Draft Registration Statement on Form S-1 submitted July 29, 2021

Our Clinical Results and Studies, page 114

We note your response to our prior comment 16. To the extent known, please expand your disclosure to address how the transfusion rates and hemostatis observed in your clinical studies compare to TURP and other alternative surgical treatments.

Reza Zadno, Ph.D.

FirstName

PROCEPT LastNameReza Zadno, Ph.D.

**BioRobotics Corporation** 

Comapany

August 16, NamePROCEPT

**BioRobotics Corporation** 2021

August

Page 2 16, 2021 Page 2 FirstName LastName

Intellectual Property, page 126

We note your response to our prior comment 18. Please revise your disclosure to specify

the type of patent protection afforded to the material patents covering your AquaBeam

Robotic System (e.g., composition of matter, use or process). Please also identify the

jurisdictions of the 25 foreign patents covering your AquaBeam Robotic System.

202-551-3662 if you have questions regarding comments on the financial statements and related

You may contact Christine Torney at 202-551-3652 or Kevin Kuhar at

matters. Please

contact Jane Park at 202-551-7439 or Thomas Kluck at 202-551-3233 with any other questions.

Sincerely,

Division of

Office of Life

Corporation Finance

Sciences

cc: Drew Capurro, Esq.